aspirin

The Most Read Scientific Articles in Interventional Cardiology of October

The Most Read Scientific Articles of October in Interventional Cardiology

1- Incidence and Prognosis of Heart Valve Embolization The incidence of peri-procedural transcatheter heart valve embolization and migration (TVEM) is as low as 1%. However, it is associated with increased morbidity and mortality. Read more HERE 2- 1000 MitraClips: Results from the World’s Most Experienced Site In September 2008, interventional physicians at the Heart and<a href="https://solaci.org/en/2019/11/07/the-most-read-scientific-articles-of-october-in-interventional-cardiology/" title="Read more" >...</a>

Reparación de la válvula tricúspide con la técnica del Mitra Clip

More Evidence on Tricuspid Valve Repair

While still lacking large-scale randomized trials, evidence is slowly building for transcatheter tricuspid valve repair. This work, presented at the TCT 2019 Congress and simultaneously published in JACC, shows that transcatheter tricuspid valve repair is not only feasible, but also likely to reduce the rates of mortality and heart failure rehospitalization compared with medical therapy alone.<a href="https://solaci.org/en/2019/10/18/more-evidence-on-tricuspid-valve-repair/" title="Read more" >...</a>

TAVI en insuficiencia aórtica pura

TAVR Offers Better Quality of Life to Low Risk Patients

Courtesy of Dr. Carlos Fava. As we all know, TAVR is gaining ground fast in the lower risk patient population, but in addition to analyzing the most important events, researchers are increasingly looking at health status, not only at hospital level, but also after one year.   This study looked into PARTNER 3 patient health status<a href="https://solaci.org/en/2019/10/16/tavr-offers-better-quality-of-life-to-low-risk-patients/" title="Read more" >...</a>

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

THEMIS: Ischemic and Hemorrhagic Events in Delicate Balance for Chronic Ticagrelor

The THEMIS study published this week in NEJM, tested chronic ticagrelor + aspirin in diabetic patients with stable coronary artery disease (CAD), but with no prior history of Myocardial infarction (MI) or stroke. The tempting hypothesis behind this study is that reducing ischemic events might increase bleeding events, and this calls for careful cost/benefit assessment. <a href="https://solaci.org/en/2019/10/11/themis-ischemic-and-hemorrhagic-events-in-delicate-balance-for-chronic-ticagrelor/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | EXCEL: Left Main Coronary Artery Angioplasty with Favorable Results at 5 Years

Courtesy of Dr. Carlos&nbsp;Fava. Unprotected left main coronary artery angioplasty with drug-eluting stents has emerged as an acceptable strategy for a select group of patients, with results comparable to those of myocardial revascularization surgery at 2 or 3&nbsp;years. However, beyond such term, we had no valid information. Researchers analyzed the 5-year follow-up results for the<a href="https://solaci.org/en/2019/10/01/tct-2019-excel-left-main-coronary-artery-angioplasty-with-favorable-results-at-5-years/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | MODEL U-SES: More Devices for High Risk of Bleeding and Short DAPT

Courtesy of SBHCI. This study tested the safety of dual antiplatelet therapy (DAPT) after only three months of bioresorbable polymer sirolimus DES implantation (Ultimaster). Secondary end point was following with P2Y12 inhibitor monotherapy after the first 3 months compared with aspirin.&nbsp; It included 1695 patients treated with sirolimus eluting Ultimaster receiving 3-month DAPT. After the<a href="https://solaci.org/en/2019/09/30/tct-2019-model-u-ses-more-devices-for-high-risk-of-bleeding-and-short-dapt/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | EVOLVE Short DAPT: Only 3-month DATP in High Risk Bleeding

Courtesy of the SBHCI. This study used the thin strut everolimus eluting stent with ultrathin abluminal bioresorbable polymer coating chromium platinum stent, basically the Synergy stent. Drug release and polymer degradation within four months facilitate endothelization and would allow a shorter DAPT. Presented during the scientific sessions of TCT 2019, this study included 2009 high<a href="https://solaci.org/en/2019/09/30/tct-2019-evolve-short-dapt-only-3-month-datp-in-high-risk-bleeding/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | Onyx ONE: Durable Polymer vs. Polymer-Free Stent with Only One Month of Dual Antiplatelet Therapy

Courtesy of the SBHCI. This is the first randomized study comparing a durable-polymer drug-eluting stent (zotarolimus-eluting stent Onyx) and a polymer-free drug-eluting stent (biolimus-A9-coated stent BioFreedom), with only one month of dual antiplatelet therapy in patients at high risk for bleeding. Onyx ONE was a study conducted at 84&nbsp;sites that randomized 1:1 2000&nbsp;total patients at<a href="https://solaci.org/en/2019/09/30/tct-2019-onyx-one-durable-polymer-vs-polymer-free-stent-with-only-one-month-of-dual-antiplatelet-therapy/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | TWILIGHT: Minimal DAPT in High Bleeding Risk Patients

Courtesy of the SBHCI. Monotherapy with a P2Y12 inhibitor after a minimum period (3 months) of dual antiplatelet antiaggregation (DAPT) is a valid treatment option to reduce bleeding in patients at high risk of bleeding complications.&nbsp; The present double-blind study presented at TCT 2019 simultaneously published in NEJM analyzed ticagrelor monotherapy (prior 3 months DAPT)<a href="https://solaci.org/en/2019/09/30/tct-2019-twilight-minimal-dapt-in-high-bleeding-risk-patients/" title="Read more" >...</a>

ESC 2019 | AFIRE: monoterapia de rivaroxabán en fibrilación auricular y enfermedad coronaria estable

ESC 2019 | AFIRE: Monotherapy with Rivaroxaban in Atrial Fibrillation and Stable CAD

In patients with atrial fibrillation and stable coronary artery disease who have not had revascularization procedures in the last 12 months, monotherapy with rivaroxaban seems the best treatment strategy compared to rivaroxaban plus antiplatelet antiaggregation. This is what resulted from the AFIRE study, presented during the ESC 2019 in Paris and published in NEJM. Monotherapy<a href="https://solaci.org/en/2019/09/06/esc-2019-afire-monotherapy-with-rivaroxaban-in-atrial-fibrillation-and-stable-cad/" title="Read more" >...</a>

Top